SCOPUS 정보 검색 플랫폼

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 5, 2014, Pages 1281-1284

Antibiotics: The changing regulatory and pharmaceutical industry paradigm

(2) Bax, Richard a,b Green, Samantha a,c

a TRANSCRIP PARTNERS LLP (United Kingdom)

b KING'S COLLEGE LONDON (United Kingdom)

c ESP Ltd (United Kingdom)

Author keywords

Adaptive design; Antibacterial use; Antibiotic pricing; Antimicrobial resistance; Narrow spectrum antibiotics; Regulatory approval

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ARTICLE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG COST; DRUG INDUSTRY; DRUG MANUFACTURE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE POLICY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; LICENSING; MULTIDRUG RESISTANCE; NEOPLASM; PHASE 1 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); DRUG DEVELOPMENT; ECONOMICS; ISOLATION AND PURIFICATION; PROCEDURES; TRENDS;

ANTI-BACTERIAL AGENTS; DRUG APPROVAL; DRUG DISCOVERY; DRUG INDUSTRY; HUMANS;

EID: 84929762051 PISSN: 03057453 EISSN: 14602091 Source Type: Journal
DOI: 10.1093/jac/dku572 Document Type: Article

Times cited : (38)

References (16)

1
- 84903739573
- EMA/254350/2012
- EMA. Pilot Project on Adaptive Licensing. EMA/254350/2012. 2014. http:// www.ema.europa.eu/docs/en_GB/document_library/Other/2014/03/ WC500163409.pdf.
- (2014) Pilot Project on Adaptive Licensing.

2
- 80051705390
- Regulatory opportunities to encourage technology solutions to antibacterial drug resistance
- Finch R and on behalf of the BSAC working party on The Urgent Need:Regenerating Antibacterial Drug Discovery and Development. Regulatory opportunities to encourage technology solutions to antibacterial drug resistance. J Antimicrob Chemother 2011; 66:1945-7.
- (2011) J Antimicrob Chemother , vol.66 , pp. 1945-1947
- Finch, R.¹

3
- 84887621675
- Antibiotic action: helping deliver action plans and strategies
- Piddock LJ. Antibiotic action: helping deliver action plans and strategies. Lancet Infect Dis 2013; 13:1009-11.
- (2013) Lancet Infect Dis , vol.13 , pp. 1009-1011
- Piddock, L.J.¹

4
- 78650250629
- CPMP/EWP/558/95 rev 2.
- EMA. Guideline on the Evaluation of Medicinal Products Indicated for Treatment of Bacterial Infections. CPMP/EWP/558/95 rev 2. 2012. http:// www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003417.pdf.
- (2012) Guideline on the Evaluation of Medicinal Products Indicated for Treatment of Bacterial Infections.

5
- 84929720190
- EMA/CHMP/351889/2013.2013
- EMA. Addendum to the Guideline on the Evaluation of Medicinal Products Indicated for Treatment of Bacterial Infections. EMA/CHMP/351889/2013.2013. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_ guideline/2013/11/WC500153953.pdf.
- Addendum to the Guideline on the Evaluation of Medicinal Products Indicated for Treatment of Bacterial Infections.

6
- 85010855433
- updated 23 September, cited 2014 14 Nov]
- Woodcock J. Three Encouraging Steps Towards New Antibiotics: FDA Voice; 2014 [updated 23 September 2014; cited 2014 14 Nov]. http:// blogs.fda.gov/fdavoice/index.php/2014/09/three-encouraging-stepstowards- new-antibiotics/.
- (2014) Three Encouraging Steps Towards New Antibiotics: FDA Voice; 2014
- Woodcock, J.¹

7
- 84874238564
- A comprehensive regulatory framework to address the unmet need for new antibacterial treatments
- Rex JH, Eisenstein BI, Alder J et al. A comprehensive regulatory framework to address the unmet need for new antibacterial treatments. Lancet Infect Dis 2013; 13:269-75.
- (2013) Lancet Infect Dis , vol.13 , pp. 269-275
- Rex, J.H.¹ Eisenstein, B.I.² Alder, J.³

8
- 84857227370
- Evidence vs. access: can twenty-first-century drug regulation refine the tradeoffs?
- Woodcock J. Evidence vs. access: can twenty-first-century drug regulation refine the tradeoffs? Clin Pharmacol Ther 2012; 91: 378-80.
- (2012) Clin Pharmacol Ther , vol.91 , pp. 378-380
- Woodcock, J.¹

9
- 84929736953
- as presented by Robert J. Guidos, JD, VP, Public Policy & Government Relations.
- IDSA. Modified from Comments Delivered at the Food and Drug Administration's (FDA) February 4, 2013 Hearing on "Creating an Alternative Approval Pathway for Certain Drugs Intended to Address Unmet Medical Need" as presented by Robert J. Guidos, JD, VP, Public Policy & Government Relations. 2013. http://www.fda.gov/downloads/ Drugs/NewsEvents/UCM340568.pdf.
- (2013) Modified from Comments Delivered at the Food and Drug Administration's (FDA) February 4, 2013 Hearing on "Creating an Alternative Approval Pathway for Certain Drugs Intended to Address Unmet Medical Need

10
- 70449645866
- CHMP/EWP/2459/02
- EMA. Reflection Paper on Methodological Issues in Confirmatory Clinical Trials Planned with an Adaptive Design. CHMP/EWP/2459/02. 2007. http:// www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003616.pdf.
- (2007) Reflection Paper on Methodological Issues in Confirmatory Clinical Trials Planned with an Adaptive Design.

11
- 84920718734
- EMA/838713/2011 Rev 1
- EMA. Guideline on Good Pharmacovigilance Practices (GVP). Module V-Risk management systems (Rev 1). EMA/838713/2011 Rev 1. 2014. http:// www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500129134.pdf.
- (2014) Guideline on Good Pharmacovigilance Practices (GVP). Module V-Risk management systems (Rev 1).

12
- 84862777400
- Adaptive licensing: taking the next step in the evolution of drug approval
- Eichler HG, Oye K, Baird LG et al. Adaptive licensing: taking the next step in the evolution of drug approval. Clin Pharmacol Ther 2012; 91:426-37.
- (2012) Clin Pharmacol Ther , vol.91 , pp. 426-437
- Eichler, H.G.¹ Oye, K.² Baird, L.G.³

13
- 0242294152
- The Witley Park Study Group. Antibiotic clinical trials-the Witley Park Symposium
- Bax RP, Gabbay F, Phillips I. The Witley Park Study Group. Antibiotic clinical trials-the Witley Park Symposium. Clin Microbiol Infect 1999; 5:774-88.
- (1999) Clin Microbiol Infect , vol.5 , pp. 774-788
- Bax, R.P.¹ Gabbay, F.² Phillips, I.³

14
- 84907473074
- London: Chatham House
- Outterson K. New Business Models for Sustainable Antibiotics. Working Groups on Antimicrobial Resistance. Paper 1. London: Chatham House, 2014.
- (2014) New Business Models for Sustainable Antibiotics. Working Groups on Antimicrobial Resistance. Paper 1.
- Outterson, K.¹

15
- 84877911547
- Innovation-drugs and diagnostics
- Finch R. Innovation-drugs and diagnostics. J Antimicrob Chemother 2007; 60 Suppl 1: i79-82.
- (2007) J Antimicrob Chemother , vol.60 , pp. i79-i82
- Finch, R.¹

16
- 0019023746
- Why data bases should not replace randomized clinical trials
- Byar DP. Why data bases should not replace randomized clinical trials. Biometrics 1980; 35:337-42.
- (1980) Biometrics , vol.35 , pp. 337-342
- Byar, D.P.¹

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.